Financials data is unavailable for this security.
View more
Year on year Bionano Genomics Inc had net income fall 75.34% from a loss of 132.60m to a larger loss of 232.49m despite revenues that grew 29.90% from 27.80m to 36.12m over the same period.
Gross margin | 28.97% |
---|---|
Net profit margin | -557.98% |
Operating margin | -509.33% |
Return on assets | -101.86% |
---|---|
Return on equity | -138.33% |
Return on investment | -123.67% |
More ▼
Cash flow in USDView more
In 2023, Bionano Genomics Inc increased its cash reserves by 234.15%, or 12.86m. Cash Flow from Financing totalled 113.82m or 315.14% of revenues. In addition the company used 125.18m for operations while cash from investing totalled 24.16m.
Cash flow per share | -3.91 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 1.14 |
---|---|
Tangible book value per share | 0.7109 |
More ▼
Balance sheet in USDView more
Current ratio | 1.63 |
---|---|
Quick ratio | 1.11 |
Total debt/total equity | 0.0477 |
---|---|
Total debt/total capital | 0.0455 |
More ▼